Approval · Notice of Compliance 38034 · 2026
TECENTRIQ: Notice of Compliance 38034
Issued July 31, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 38034
- Date
- July 31, 2026
- Company
- Hoffmann-La Roche LimitedMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: TECENTRIQ, in combination with lurbinectedin, is indicated for the maintenance treatment of adult patients with ES-SCLC whose disease has not progressed following first-line induction therapy with atezolizumab, carboplatin and etoposide. TECENTRIQ SC, in combination with lurbinectedin, is indicated for the maintenance treatment of adult patients with ES-SCLC whose disease has not progressed following first-line induction therapy with atezolizumab, carboplatin and etoposide
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TECENTRIQ | Not yet assigned | — |
| TECENTRIQ SC | Not yet assigned | — |
Medicinal ingredients
- ATEZOLIZUMAB 840 MG per 14ML
- ATEZOLIZUMAB 1,200 MG per 20ML
- ATEZOLIZUMAB 125 MG per ML